All articles tagged with #wuxi apptec
A proposed biosecurity bill aimed at regulating Chinese biotech contractors, such as WuXi AppTec, was not included in the end-of-year defense package, which was considered its best opportunity for passage in the current session of Congress.
US intelligence officials informed Congress that WuXi AppTec transferred a US client's intellectual property to Chinese authorities without consent, raising concerns about the company and other unnamed Chinese firms engaging in activities contrary to US interests.
U.S. intelligence officials briefed senators on concerns that Chinese pharmaceutical firm WuXi AppTec had transferred U.S. intellectual property to Beijing without consent, potentially for use by China's military. The proposed legislation aims to restrict U.S. government funds going to Chinese companies engaged in such activities. WuXi AppTec denied unauthorized transfers and stated compliance with U.S. regulations. The briefing coincided with the Senate's consideration of a bill restricting business with Chinese biotech companies on national security grounds, and led to lobbying group BIO reversing its opposition to the bill, citing national security concerns.
The Biotechnology Innovation Organization (BIO) is ending its association with Chinese company WuXi AppTec following accusations of being a US national security risk. This decision comes as members of Congress target WuXi and other Chinese healthcare firms, with legislation potentially banning them from working in the US or with US companies.
Bipartisan lawmakers are urging the US government to investigate Chinese contract research and manufacturing giants WuXi AppTec and WuXi Biologics for alleged ties to the Chinese military, requesting that the companies be added to multiple US government control lists.